Spanish privately held pharmaceutical company Esteve has entered into an agreement to acquire the Infusion Specialty Therapies Business Unit of US-based TerSera, marking a significant expansion of its pharma and life sciences operations in the United States. 

The transaction adds two established, on-market specialty medicines and a dedicated commercial and medical team, strengthening Esteve’s position in highly specialised therapeutic areas.

The acquired business unit includes Prialt (ziconotide intrathecal infusion) and Quzyttir (cetirizine hydrochloride injection), both approved by the US Food and Drug Administration. 

Prialt is currently the only FDA-approved non-opioid treatment indicated for the management of severe chronic pain in adult patients who require intrathecal therapy and are intolerant of, or refractory to, other treatments such as systemic analgesics or intrathecal morphine. The product is already marketed in Europe by Esteve.

Quzyttir is the first and only injectable second-generation H1 antihistamine approved by the FDA for the treatment of acute urticaria in adults and children aged six months and older. Through the acquisition, Esteve will obtain worldwide rights to Quzyttir across all territories except China, while also consolidating its global rights to Prialt.

The agreement supports Esteve’s strategy to deepen its US presence by combining specialty assets with an experienced team of sales, marketing and medical professionals. The addition of these capabilities enhances the company’s ability to commercialise and support complex therapies within regulated healthcare markets.

While the financial terms of the transaction were not disclosed, the deal positions Esteve to leverage its existing expertise in specialty pharmaceuticals while expanding its reach beyond Europe. 

By securing global rights to both products, the company gains greater control over lifecycle management, market development and long-term value creation within its pharma and life sciences portfolio.

Explore how this acquisition reshapes Esteve’s US specialty medicines strategy and global growth plans.

(Photo Credits to Esteve)